Since the approval of Kymriah (a CD19 CAR-T product) in 2017 by the US Food and Drug Administration (FDA) for patients with B-cell acute lymphoblastic leukemia (B-ALL) (Maude et al., 2018) Five other CAR-T products have been approved by this authority, including Yescarta (a CD19 CAR-T product approved in 2017) (Neelapu et al., 2017), Tecartus (a CD19 CAR-T product approved in 2020) (FDA, 2021a), Breyanzi (a CD19 CAR-T product approved in 2021) (FDA, 2021c), Abecma (a BCMA CAR-T product approved in 2021) (FDA, 2021b), and Carvykti (a BCMA CAR-T product approved in 2022) (FDA, 2022). This evidence concerns the gene CD19 and B-cell acute lymphoblastic leukemia.